In recent years, the introduction of mRNA vaccines for SARS-CoV2 and RSV has highlighted the success of the mRNA technology platform. Designing mRNA sequences involves multiple components and requires balancing several parameters, including enhancing transcriptional efficiency, boosting antigenicity, and minimizing immunogenicity. Moreover, changes in the composition and properties of delivery vehicles can also affect vaccine performance. Traditional methods of experimentally testing these conditions are time-consuming, labor-intensive and costly, necessitating advanced optimization strategies. Recently, the rapid development of computational tools has significantly accelerated the optimization process for mRNA vaccines. In this review, we systematically examine computation-aided approaches for optimizing mRNA components, including coding and non-coding regions, and for improving the efficiency of lipid nanoparticle (LNP) delivery systems by focusing on their composition, ratios, and characterization. The use of computational tools can significantly accelerate mRNA vaccine development, enabling rapid responses to emerging infectious diseases and supporting the development of precise, personalized therapies. These approaches may guide the future direction of mRNA vaccine development. Our review aims to provide integrated constructive support for computer-aided mRNA vaccine design.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1152/physiol.00047.2024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing the performance of an in vitro RNA biosensor through iterative design of experiments.
Biotechnol Prog
March 2025
Centre for Synthetic Biology, Imperial College London, London, UK.
The quality control of RNA has become increasingly crucial with the rise of mRNA-based vaccines and therapeutics. However, conventional methods such as LC-MS often require specialized equipment and expertise, limiting their applicability to high throughput experiments. Here, we optimize a previously characterized RNA integrity biosensor, that provides a simple colorimetric output, using Design of Experiments (DoE).
View Article and Find Full Text PDFIncidence of dynamic seroconversion in subjects received the first dose of the SARS-COV-2 vaccine (AstraZeneca, Moderna and Pfizer) in Kinshasa, Democratic Republic of Congo: prospective cohort study.
BMC Infect Dis
March 2025
Department of Microbiology, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
Background: Mass vaccination efforts worldwide have reduced the incidence of COVID-19, but despite this reduction, seroconversion studies in sub-Saharan Africa are limited. The aim of this study is to assess the incidence of seroconversion in subjects who received the first dose of SARS-COV-2 vaccine (AstraZeneca, Moderna and Pfizer) in Kinshasa.
Methods: This was a prospective study recruiting 918 subjects vaccinated at the Cliniques Universitaires de Kinshasa between 19 April and 14 August 2021.
Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.
Vaccine
March 2025
Medical Evidence, Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Background: Booster doses of COVID-19 vaccines are required to maintain protection against SARS-CoV-2. However, real-world evidence from South America, needed to inform optimal vaccination strategies, is lacking. Herein, we present the final analysis of REFORCO-Brazil, a large-scale assessment of relative vaccine effectiveness (rVE) of second boosters (vs first boosters) against hospitalization with COVID-19.
View Article and Find Full Text PDFDual mRNA nanoparticles strategy for enhanced pancreatic cancer treatment and β-elemene combination therapy.
Proc Natl Acad Sci U S A
March 2025
Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
Pancreatic ductal adenocarcinoma (PDAC) is notoriously immune-resistant, limiting the clinical efficacy of single-agent immune modulators and thereby necessitating the exploration of multimodal immunotherapy combinations. Traditional approaches combining conventional immune checkpoint inhibitors with neoantigen vaccines have shown some promise in treating PDAC but are often compromised by intratumoral T lymphocyte exhaustion and systemic toxicity. Hence, novel approaches are needed to address these challenges.
View Article and Find Full Text PDFBooster effect of the fourth dose of the SARS-CoV-2 mRNA vaccine in kidney transplant recipients.
Clin Exp Nephrol
March 2025
Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.
Background: Solid organ transplant recipients taking immunosuppressive drugs are at greater risk of severe COVID-19 than the general population. In particular, kidney transplant recipients (KTRs) are known to have lower seropositivity after basal doses of SARS-CoV-2 vaccines, and the strategy of administering booster doses in these immunocompromised individuals has been promoted worldwide.
Methods: This study evaluated the effect of a fourth dose (D4) of SARS-CoV-2 vaccine in Japanese KTRs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!